PMID- 38057876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231209
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 15
IP  - 1
DP  - 2023 Dec 7
TI  - Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid 
      deposition and improves renal oxygenation levels in newly diagnosed type 2 
      diabetes mellitus patients: a randomized controlled trial.
PG  - 256
LID - 10.1186/s13098-023-01236-1 [doi]
LID - 256
AB  - BACKGROUND: Sodium-dependent glucose transporter 2 inhibitor (SGLT2i) has the 
      advantages of effectively lowering blood glucose levels and improving renal 
      outcomes in diabetic patients. This study evaluated the effect of canagliflozin 
      on intrarenal lipid content and oxygenation in newly diagnosed type 2 diabetes 
      mellitus (T2DM) patients. METHODS: A total of 64 newly diagnosed T2DM patients 
      with normal renal function were randomly divided into canagliflozin (n = 33) and 
      glimepiride control (n = 31) groups. All patients underwent functional magnetic 
      resonance imaging (fMRI) scanning to assay patients' intrarenal lipid content and 
      oxygenation level before and after 24 weeks of treatment. Furthermore, the 
      relationship between body mass index and intrarenal lipid content in T2DM 
      patients was analyzed and the correlation between changes in intrarenal lipid 
      content and improvements in renal hypoxia was further assessed. RESULTS: The 
      canagliflozin group had a greater decrease in body weight and blood uric acid 
      level than the glimepiride group (all P < 0.05). The intrarenal lipid content 
      could be significantly reduced after canagliflozin treatment for 24 weeks. The 
      R2* values, a parameter for quantifying the oxygen content in tissues and is 
      inversely related to the oxygen content, of the renal cortex and medulla in the 
      canagliflozin group decreased from the baseline by 6.40% (P < 0.01) and 12.09% 
      (P = 0.000007), respectively. In addition, the degree of reduction of fat 
      fraction (DeltaFF) in the kidneys of the canagliflozin group was correlated with the 
      degree of improvement of oxygenation level (DeltaR2*) in the renal cortex (r = 0.422, 
      P = 0.014). CONCLUSIONS: The early renal protective effect of SGLT2i in newly 
      diagnosed T2DM patients may be partly attributed to the amelioration of renal 
      hypoxia via the alleviation of ectopic lipid deposition in the kidneys. TRIAL 
      REGISTRATION: Chu Hsien-I Memorial Hospital of Tianjin Medical University 
      (ChiCTR2000037951).
CI  - (c) 2023. The Author(s).
FAU - Zhang, Li
AU  - Zhang L
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Wang, Tongdan
AU  - Wang T
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Kong, Yan
AU  - Kong Y
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Sun, Haizhen
AU  - Sun H
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Zhang, Yuling
AU  - Zhang Y
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Wang, Junmei
AU  - Wang J
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Wang, Zhida
AU  - Wang Z
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Lu, Shan
AU  - Lu S
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China.
FAU - Yu, Pei
AU  - Yu P
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China. yupei@tmu.edu.cn.
FAU - Zhou, Saijun
AU  - Zhou S
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Beichen District, No.6 North Huanrui 
      Rd, Tianjin, 300134, China. zhousaijun@tmu.edu.cn.
LA  - eng
GR  - ZXY-ZDSYS2020-4/Scientific Research Funding of Tianjin Medical University Chu 
      Hsien-I Memorial Hospital, Tianjin Key Laboratory of Metabolic Diseases/
GR  - ZXY-ZDSYSZD2022-1/Scientific Research Funding of Tianjin Medical University Chu 
      Hsien-I Memorial Hospital, Tianjin Key Laboratory of Metabolic Diseases/
GR  - 22KPHDRC00060/Project of Science and Technology Popularization Activity in 
      Tianjin/
GR  - 2022-N-02-07/China Endocrine Metabolism Talent Research Fund/
PT  - Journal Article
DEP - 20231207
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC10702117
OTO - NOTNLM
OT  - Canagliflozin
OT  - Hypoxia
OT  - Intrarenal lipid content
OT  - Renal oxygenation level
OT  - Type 2 diabetes
COIS- The authors declare that they have no competing interests.
EDAT- 2023/12/07 06:42
MHDA- 2023/12/07 06:43
PMCR- 2023/12/07
CRDT- 2023/12/07 00:07
PHST- 2023/08/30 00:00 [received]
PHST- 2023/11/27 00:00 [accepted]
PHST- 2023/12/07 06:43 [medline]
PHST- 2023/12/07 06:42 [pubmed]
PHST- 2023/12/07 00:07 [entrez]
PHST- 2023/12/07 00:00 [pmc-release]
AID - 10.1186/s13098-023-01236-1 [pii]
AID - 1236 [pii]
AID - 10.1186/s13098-023-01236-1 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2023 Dec 7;15(1):256. doi: 10.1186/s13098-023-01236-1.